ArticleZeitschrift fur Rheumatologie2026
[Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry].
Article in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegulatory safety recommendations regarding Janus kinase inhibitors (JAKi) led to a marked decline in new prescriptions in Germany. In the meantime, professional medical societies have also issued differentiated recommendations.
objectivesThe aim was to investigate the RHADAR (RheumaDatenRhePort) registry to check whether JAKi prescriptions recovered thereafter. MATERIALS AND
methodsA retrospective analysis of new prescriptions for JAKi, tumor necrosis factor inhibitors (TNFi), and interleukin‑6 receptor inhibitors (IL-6Ri) in patients with rheumatoid arthritis between 1 April 2020, and 30 September 2024. The primary endpoint was the proportion of JAKi among all new prescriptions of these three drug classes per half-year. The treatment line of JAKi use was additionally assessed.
resultsA total of 3492 treatment initiations were recorded in the registry during the observation period (TNFi: n = 1770, 50.7%, JAKi: n = 1269, 36.3%, IL-6Ri: n = 453, 13.0%). The proportion of JAKi initially rose from 29.5% (Q2-Q3/2020) to 46.9% (Q2-Q3/2021), followed by a decline to 24.4% (Q2-Q3/2023) after the regulatory safety communications. Since Q4/2023, a renewed increase has been observed (32.8%), though not yet reaching previous peak levels. JAKi were increasingly shifted from early to advanced treatment lines (≥ 3rd line).
conclusionFollowing the decline in JAKi prescriptions due to European Medicines Agency safety recommendations, a renewed increase has been observed. Since then, JAKi have been predominantly used in later treatment lines, indicating a more differentiated approach to this drug class.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.